Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
An RMAT designation includes those benefits included in the fast track and breakthrough therapy pathways such as a priority review, along with early and enhanced FDA interactions. The RMAT tag also permits the use of surrogate endpoints in clinical trials studying the therapy, which can lead to accelerated approval.
Shares in the US biotech rose 9.5% at market open compared to a pre-announcement 15 July market close. Kyverna has a market cap of $427m. The RMAT application’s success was based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named patient treatment option, according to a 16 July press release. See Also:Explainer: Labour has been elected in the UK – now what?
Source: Pharmaceutical Technology
Kyverna has not revealed further information about the US trial, with the biotech’s CEO Peter Maag saying “we are eager to begin generating data”. Kyverna is considering cell therapy treatments beyond blood cancers, the space in which many CAR-T treatments are currently approved to treat. KVY-101 is being evaluated in sponsored Phase I/II and Phase II trials in the US and Germany in indications such as refractory lupus nephritis (NCT05938725), multiple sclerosis, and myasthenia gravis. The biotech reported positive Phase I results for the cell therapy in multiple sclerosis patients in April this year, the indication for which the drug has fast track status from the FDA. Kyverna went public earlier this year, raising $319m in the process. The initial public offering (IPO), which was larger than expected, saw the company sell 14.5 million shares for $22 each. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
Source: Pharmaceutical Technology
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy